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Abstract
Aims: The efficacy of flash glucose monitoring (flash GM) systems has been demon-
strated by improvements in glycaemia; however, during high rates of glucose flux, the
performance of continuous glucose monitoring systems was impaired, as detailed in previ-
ous studies. This study aimed to determine the performance of the flash GM system dur-
ing daily-life glycaemic challenges such as carbohydrate-rich meals, bolus insulin-induced
glycaemic disturbances and acute physical exercise in individuals with type 1 diabetes.
Materials and methods: This study comprised four randomized trial visits with alter-
nating pre- and post-exercise bolus insulin doses. Throughout the four 14-hour inpa-
tient phases, 19 participants received three carbohydrate-rich meals and performed
moderate-intensity exercise. Venous blood glucose and capillary blood glucose during
exercise was compared to interstitial glucose concentrations. Flash GM accuracy was
assessed by median absolute relative difference (MARD) (interquartile range [IQR])
using the Bland–Altman method and Clark error grid, as well as according to guide-
lines for integrated CGM approvals (Class II–510(K)).
Results: The overall MARD (IQR) during inpatient phases was 14.3% (6.9%–22.8%),
during hypoglycaemia (≤3.9 mmol/L) was 31.6% (16.2%–46.8%), during euglycaemia
(4.0 mmol/L − 9.9 mmol/L) was 16.0% (8.5%–24.0%) and during hyperglycaemia
(≥10 mmol/L) was 9.4% (5.1%–15.7%). Overall Bland–Altman analysis showed a bias
(95% LoA) of 1.26 mmol/L (−1.67 to 4.19 mmol/L). The overall MARD during acute
exercise was 29.8% (17.5%–39.8%), during hypoglycaemia was 45.1% (35.2%–
51.1%), during euglycaemia was 30.7% (18.7%–39.2%) and during hyperglycaemia
was 16.3% (10.0%–22.8%).
Conclusion: Flash GM interstitial glucose readings were not sufficiently accurate
within the hypoglycaemic range and during acute exercise and require confirmatory
blood glucose measurements.
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1 | INTRODUCTION
In July 2018 the US Food and Drug Administration (FDA) approved
the Freestyle Libre flash glucose monitoring (flash GM) system
(Abbott Diabetes Care Inc, USA) to monitor interstitial glucose con-
centration without obtaining a capillary blood sample from the finger-
tip for management of type 1 and type 2 diabetes in individuals
18 years of age and older.1 The beneficial effects of integrating flash
GM technology into diabetes management include: reduced time
spent in hypoglycaemia, improved glycaemic variability,2 lower HbA1c
levels3 and increased numbers of readings per day4 in individuals with
type 1 diabetes.5
Although the flash GM system demonstrated good efficacy in
chronic glucose monitoring settings, the accuracy of acute continuous
glucose monitoring (CGM) systems was impaired during periods of
high rates of change in glucose.6 From a physiological point of view, a
time lag was observed in the interval needed for glucose to diffuse
from the bloodstream into the interstitium.6 In general, use of CGM
systems involves a struggle with sensor accuracy during
hypoglycaemia and exercise, as shown for both professional (iPro2,
Enlite 2, Medtronic, USA) and personal (Minimed 640G, Medtronic;
Freestyle Libre 1, Abbott, USA; Dexcom G4 Platinum, Dexcom, USA)
CGM systems.7-9 The performance of the flash GM system sensor
was found to be accurate, with an overall mean absolute relative dif-
ference of approximately 13% under routine environmental condi-
tions.8 During acute glycaemic challenges such as physical exercise
or following carbohydrate-rich meals and high doses of exogenous
insulin, the interstitial glucose response may be further delayed.
Pleus et al. showed that during periods of rapidly changing blood
glucose concentrations of more than −0.2 mmol/L/minute and
+0.2 mmol/L/minute the mean absolute relative difference deterio-
rated from 12.6% and 11.3% to 24.9% and 29.6% for the Dexcom G4
Platinum CGM system (Dexcom, USA).10 Taking this information into
account, there is a need to investigate flash GM performance during
exogenously induced glucose excursions to ensure patient safety.
Therefore, the aim of this study was to determine the sensor accuracy
of the Freestyle Libre flash GM system in individuals with type 1 diabe-
tes during the acute glycaemic challenges of carbohydrate-rich meal
ingestion, bolus insulin administration and aerobic physical exercise.
2 | METHODS
This study is an analysis of a predefined secondary outcome of a clini-
cal trial registered at the German Clinical Trials Register (DRKS.de;
DRKS.de; DRKS00013509). This single-centre, randomized, open-
label, four-period 14-hour inpatient cross-over trial was performed in
line with Good Clinical Practice and the Declaration of Helsinki. The
study protocol was approved by the ethics committee of Health and
Care Research Wales, UK (16/WA/0394) and the local health author-
ity. All participants gave written informed consent prior to any trial-
related activities.
2.1 | Eligibility criteria
Inclusion criteria are as follows: diagnosis of type 1 diabetes at least
12 months previously; age 18 to 65 years; body mass index of 18.0 to
29.4 kg/m2; use of multiple daily injections (MDI) of insulin for at least
12 months; mass-specific peak oxygen uptake (VO2peak) of more than
20 mL/kg/minute; and status of being physically active as assessed by
the International Physical Activity Questionnaire Short Form (IPAQ-
SF). Main exclusion criteria were: presence of a life-threatening dis-
ease; proliferative retinopathy or maculopathy; severe neuropathy;
recurrent severe hypoglycaemia (more than one severe hypoglycaemia
event during the previous 12 months); hypoglycaemia unawareness as
judged by the investigator; hospitalization for diabetic ketoacidosis
during the previous 6 months; and any other condition that would
interfere with trial participation or evaluation of results as judged by
the investigator.
2.2 | Screening visit
Anthropometry, body composition, resting cardiovascular markers and
HbA1c were measured. Participants performed a peak cardio-
pulmonary exercise (CPX) test using a semi-recumbent cycle ergome-
ter (Corival Recumbent, Lode, Groningen, The Netherlands).11 CPX
testing comprised a 3-minute resting period without pedalling,
followed by a 3-minute warm-up phase with pedalling at 20 W (W).
Thereafter, the exercise workload increased at the end of each minute
by 10, 15 or 20 W, dependent on the anticipated functional capacity
of the participant, as assessed by an experienced exercise physiologist.
After reaching maximum volitional exhaustion, participants performed
an active cool-down for 3 minutes at 20 W, followed by a 3-minute
passive cool-down period without pedalling. Maximum volitional
exhaustion was defined by one of the following parameters: a lactate
concentration greater than10 mmol/L; a respiratory exchange ratio
(RER) greater than 1.1; a plateau in oxygen uptake (VO2); or inability
to maintain a pedalling cadence of more than 50 rpm (rpm) for 5 sec-
onds.12 During CPX testing, respiration measurement (METAMAX 3B;
Cortex Biophysik GmbH, Leipzig, Germany), heart rate measurement
(S410, Polar Electro, Kmpele, Finland) and electrocardiogram measure-
ment (eMotion Faros 180, Bittium Biosignals Ltd, Oulu, Finland) were
ongoing. Capillary blood glucose and blood lactate from earlobe sam-
pling (20 μL) were taken as follows: at the end of the passive and
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active warm-up periods; at the end of each incremental step in exer-
cise; and at the end of the active and passive cool-down periods
(Biosen C-line, EKF Diagnostic, Barleben, Germany). Blood glucose
was measured to minimize the risk of hypoglycaemia and blood lactate
was evaluated to prescribe exercise intensity by means of the mid-
point of the first (LTP1) and the second lactate turn points (LTP2)
(~65% of VO2peak). If participants were using insulins other than insu-
lin aspart (Novo Nordisk, A/S, Denmark) and insulin degludec U100
(Novo Nordisk, A/S), they were switched over to these during a maxi-
mum period of 28 days prior to the study. This ensured a homogenous
study cohort and allowed for a stable therapy, defined as a pre-
breakfast self-measured blood glucose concentration between 4.0 and
7.0 mmol/L over three consecutive days. If participants were using
insulin detemir (Novo Nordisk, A/S) or insulin glargine U100 (Sanofi,
France) prior to the trial, the first dose of insulin degludec (Novo
Nordisk, A/S) was 80% of their pre-study total basal insulin dose. Par-
ticipants using insulin glargine U300 (Sanofi) were switched over to
insulin degludec (Novo Nordisk, A/S) with a 1:1 dose at the beginning.
If participants were already using insulin degludec, they were also
expected to achieve the titration target within 28 days. If adjustment
of the dose of insulin degludec (Novo Nordisk, A/S) was required, this
was undertaken every 3 days. Participants received an unblinded flash
GM system (FreeStyle Libre, Abbott Diabetes Care Inc., USA) and
spare sensors. Participants were trained in use of the system and the
first flash GM sensor was inserted under instruction by the research
team. Participants were told to change the sensor at least 48 hours
before each trial visit to avoid sensor expiration during the research
period and to avoid assessment of flash GM performance during the
initial warm-up period.
2.3 | Trial visits
Trial visits were separated by at least five working days. Participants
were randomized to the following alternating pre- and post-exercise
bolus insulin doses:
• 50%-reduced pre-exercise and 50%-reduced post-exercise dose of
insulin aspart with a carbohydrate-rich meal.
• Regular pre-exercise and regular post-exercise dose of insulin
aspart.
• 50%-reduced pre-exercise and regular post-exercise dose of insulin
aspart.
• Regular pre-exercise and 50%-reduced post-exercise dose of insu-
lin Aspart.
Throughout each of the four 14-hour inpatient phases, partici-
pants received three carbohydrate-rich meals and venous blood glu-
cose concentration was compared to interstitial glucose concentration
(Figure 1). During exercise, only capillary blood was obtained from the
earlobe, with resultant glucose concentrations compared to interstitial
glucose concentration; these values were analysed separately because
of collection from a different compartment. In this study, only scanned
data were used for assessment of the flash GM system; at the time a
blood sample was taken, a scan was performed using the flash GM
system and these data were assessed for accuracy.13 Both values
were recorded in a case report form.
At the pre- and post-exercise meal, participants consumed 1 g of
carbohydrates per kilogram of bodyweight, with a regular dose or
50% dose of bolus insulin. Additionally, a pre-bedtime snack, con-
sisting of 0.4 g of carbohydrates per kilogram of bodyweight, was con-
sumed without a dose of bolus insulin.14 The basal insulin dose
remained unchanged for the purpose of this study. A total of 13 sam-
ples were collected from an antecubital vein and analysed using the
fully enzymatic Biosen C-Line system (EKF Diagnostic). During exer-
cise testing, capillary samples were collected from the earlobe and
analysed using the Biosen C-Line system. Exercise blood glucose test-
ing comprised nine sample time points; however, there were fewer
time points in the case of a level 1 hypoglycaemia episode (blood glu-
cose ≤3.9 mmol/L).15
2.4 | Moderate-intensity exercise testing
Exercise testing comprised four 45-minute moderate-intensity exer-
cise sessions, defined as exercise intensity at the midpoint of LTP1
and LTP2, each session separated by at least five working days. In the
case of level 1 hypoglycaemia during exercise testing, participants
received 10 g of carbohydrates via a glucose gel and exercise testing
was discontinued. Initiation of exercise testing was delayed by
10 minutes if blood glucose concentration was below 6 mmol/L, and
10 g of carbohydrates were given. This pre-exercise procedure was
repeated as often as required to reach a blood glucose concentration
above 6 mmol/L before initiation of exercise. Capillary blood glucose
was measured at the end of the warm-up period and every 7 minutes
during exercise testing. CPX testing variables were measured continu-
ously, as detailed during maximum CPX testing.
2.5 | Statistical analyses
Data were analysed for normal distribution using Shapiro–Wilk testing
to assess whether median or mean absolute relative difference must be
shown. Flash GM sensor performance was analysed using median abso-
lute relative difference (MARD) (IQR), the Bland–Altman method and
the Clarke error grid, as well as according to guidelines for integrated
CGM approvals (Class II–510(K)).16 The Clarke error grid is divided into
zones to evaluate the risk caused by inaccuracy of measurement. Values
in zone A reflect no effect on clinical action; values in zone B represent
altered clinical action with small or no significant effect on clinical out-
come; values in zone C represent altered clinical action with the proba-
bility of affecting clinical outcome; values in zone D represent altered
clinical action that could have significant medical risk; and values in zone
E represent altered clinical action that could have dangerous conse-
quences. Overall assessment of data, excluding those concerning exer-
cise, and data concerning exercise phases, excluding resting conditions,
were stratified for glycaemic ranges, defined as hypoglycaemia level
1 (≤3.9 mmol/L), euglycaemia (4.0–9.9 mmol/L) and hyperglycaemia
(≥10 mmol/L).17 Furthermore, data were stratified for day-time
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(6:00 AM–12:00 AM) and night-time (12:01 AM–5:59 AM) periods.
Rate of change in glucose was calculated for the four 14-hour inpatient
phases, excluding exercise, and was analysed separately during exercise,
during the post-exercise day-time period and during the night-time
period. This stratification was based on the expected rate of change in
glucose for each period. Only data of participants who performed at
least one 14-hour in-patient phase were used. A post-hoc sample size
calculation was performed, using data from the night-time period, which
was the most accurate, accompanied by the lowest numbers of points
of comparison. Considering 273 points of comparison and α = 0.05, we
achieved a power of ≥95% to detect an absolute median difference of
0.70 mmol/L in comparison of venous blood glucose and interstitial glu-
cose concentration.
3 | RESULTS
Among 23 screened individuals with type 1 diabetes, 19 were
included in the analysis and were involved in at least one 14-hour in-
patient phase. Four individuals were excluded according to pre-
defined inclusion criteria. Sixteen participants complied with all four
trial visits, one participant made three trial visits and two participants
made one trial visit. The two individuals who did not make all trial
visits withdrew from the study for personal reasons and one individual
was excluded because of unstable insulin therapy. The four women
and 15 men who completed the study had a mean ± SD age of
35 ± 15 years, a body mass index of 26 ± 3 kg/m2, HbA1c of 56 ±
15 mmol/mol (7.3% ± 1.4%), a diabetes duration of 16 ± 11 years and a
total daily insulin dose of 50 ± 23 IU. Before initiation of the study, all
participants were using insulin aspart (Novo Nordisk, A/S) as bolus insu-
lin, eight were using insulin glargine U100 (Sanofi), seven were using
insulin detemir (Novo Nordisk, A/S), two were using insulin degludec
U100 (Novo Nordisk, A/S) and one was using insulin glargine U300
(Sanofi) as basal insulin. Among 824 potential points of comparison for
interstitial glucose and venous blood glucose, 821 were available. Dur-
ing 69 exercise sessions, 41 participants discontinued prematurely
because of exercise-induced hypoglycaemia (≤3.9 mmol/L). During
exercise testing, 470 of 475 potential points of comparison were avail-
able. With the regular pre-exercise bolus insulin dose, 28 episodes of
hypoglycaemia occurred, whereas after a 50%-reduced pre-exercise
bolus insulin dose only 13 episodes of hypoglycaemia occurred. Initial
blood glucose concentration was 9.7 ± 3.1 mmol/L with the regular
pre- and post-exercise bolus insulin dose, 9.9 ± 2.4 mmol/L with the
50% reduced pre- and post-exercise bolus insulin dose, 9.2 ± 1.9 mmol/L
with the pre-exercise regular and post-exercise 50%-reduced bolus
insulin dose and 10.0 ± 2.3 mmol/L with the pre-exercise 50%-reduced
and post-exercise regular bolus insulin dose. The time until reaching
exercise-induced hypoglycaemia was 37 ± 11 minutes with the regular
pre- and post-exercise bolus insulin dose, 41 ± 7 minutes with the 50%-
reduced pre- and post-exercise bolus insulin dose, 35 ± 7 minutes with
the pre-exercise regular and post-exercise 50%-reduced bolus insulin
F IGURE 1 Study flow chart detailing time points of blood glucose collection, carbohydrate (CHO)-rich meals and insulin aspart injections. Red
lines = venous blood glucose sampling. Red dotted line = capillary blood glucose sampling obtained from earlobe during exercise
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dose and 40 ± 9 minutes with the pre-exercise 50%-reduced and post-
exercise regular bolus insulin dose.
Overall MARD was 14.3% (IQR 6.9%–22.8%), during hypoglycaemia
was 31.6% (16.2%–46.8%), during euglycaemia was 16.0% (8.5%–
24.0%) and during hyperglycaemia was 9.4% (5.1%–15.7%). When data
were stratified for time of day, based on the expected alternating rate of
change in glucose, day-time MARD was 18.0% (9.8%–27.5%), during
exercise was 29.8% (17.5%–39.8%) and during the night was 8.6%
(4.0%–14.5%). During exercise and periods of hypoglycaemia, MARD
was 45.1% (35.2%–51.1%), during euglycaemia was 30.7% (18.7–39.2%)
and during hyperglycaemia was 16.3% (10.0%–22.8%) (Table 1).
Systematic assessment of the accuracy of the flash GM system in
comparison with reference blood glucose concentration assessed using
the Bland–Altman method resulted, overall, in an over-estimation of
flash GM values compared to reference blood glucose values (bias,
1.26 mmol/L, with 95% limits of agreement, from −1.67 mmol/L to
4.19 mmol/L). During exercise, the flash GM system overestimated ref-
erence blood glucose concentration by 2.27 mmol/L, with 95% limits
of agreement from −0.64 mmol/L to 6.08 mmol/L (Figure 2).
Data from assessment of the performance of the flash GM system
according to guidelines for integrated CGM approvals (Class II–510
(K)) are shown in Table 2.
The Clarke error grid showed that, overall, 56% of values were
located in zone A, 35% in zone B, 9% in zone D, and no values were
located in zones C and E. During exercise, 26% of values were located
in zone A, 52% in zone B, 22% in zone D, and no values were located
in zones C and E (Figure 3).
TABLE 1 Median absolute relative difference (MARD) and
interquartile range (IQR) between interstitial glucose and reference
blood glucose
Flash GM accuracy
MARD
(IQR)
Overall 14.3% (6.9%–22.8%)
n = 821
Hypoglycaemia (≤3.9 mmol/L) 31.6% (16.2%–46.8%)
n = 75
Euglycaemia (3.9–9.9 mmol/L) 16.0% (8.5%–24.0%)
n = 508
Hyperglycaemia (≥10 mmol/L) 9.4% (5.1%–15.7%)
n = 238
Day-time (6:00 AM–12:00 AM) 18.0% (9.8%–27.5%)
n = 548
Night-time (12:01 AM–05:59 AM) 8.6% (4.0%–14.5%)
n = 273
During exercise
Overall
29.8% (17.5%–39.8%)
n = 470
During exercise
Hypoglycaemia (≤3.9 mmol/L)
45.1% (35.2%–51.1%)
n = 70
During exercise
Euglycaemia (3.9–9.9 mmol/L)
30.7% (18.7%–39.2%)
n = 306
During exercise
Hyperglycaemia (≥10 mmol/L)
16.3% (10.0%–22.8%)
n = 94
F IGURE 2 Comparison of interstitial glucose and reference blood glucose via the Bland–Altman method, displaying bias and 95% levels of
agreement (95% LoA). A, Overall data; B, Exercise. Overall, the flash GM system overestimated the reference venous blood glucose concentration
by 1.26 mmol/L, with 95% limits of agreement from −1.67 mmol/L to 4.19 mmol/L. During exercise, the flash GM system overestimated the
reference capillary blood glucose concentration by 2.27 mmol/L, with 95% limits of agreement from −0.64 mmol/L to 6.08 mmol/L
TABLE 2 Assessment of performance of the flash GM system
compared to venous blood glucose concentration according to
guidelines for integrated CGM approvals (Class II–510(K))
Measured accuracy:
Lower bound of one-
sided 95% CI
Required accuracy:
Lower bound of one-
sided 95% CI
Overall 68% within ±20% >87% within ±20%
Euglycaemia
(3.9–9.9 mmol/L)
48% within ±15% >70% within
±15%
Euglycaemia
(3.9–9.9 mmol/L)
97% within ±40% >99% within ±40%
Hypoglycaemia
(≤3.9 mmol/L)
32% within
±0.8 mmol/L
>85% within
±0.8 mmol/L
Hypoglycaemia
(≤3.9 mmol/L)
39% within
±2.2 mmol/L
>98% within
±2.2 mmol/L
Hyperglycaemia
(≥10 mmol/L)
74% within ±15% >80% within ±15%
Hyperglycaemia
(≥10 mmol/L)
100% within ±40% >99% within ±40%
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The median and interquartile range of the rate of change in glucose
was 0.15 mmol/L/min (0.098–0.2 mmol/L/min) during exercise,
0.03 mmol/L/min (0.014–0.061 mmol/L/min) during the post-exercise
day-time period and 0.007 mmol/L/min (0.001–0.017 mmol/L/min)
during the night.
4 | DISCUSSION
This is the first study to assess the performance of the flash GM sys-
tem with different rates of change in glucose in a clinical research
facility setting, comprising acute daily-life challenges such as
carbohydrate-rich meals, bolus insulin administration and physical
exercise. MARDs' for the night-time period were similar to findings
of a recent study in which a mean absolute relative difference of
13% ± 11% was found for the flash GM system.8 During acute exer-
cise, the results of our study using the flash GM system deviated con-
siderably from those of Aberer et al., who found a mean absolute
relative difference of 9% ± 6%, while we found a MARD of 29.8%
(17.5%–39.8%). We have recently shown that use of the flash GM
system during physical exercise, with the same mean exercise inten-
sity as that in the present study, revealed a MARD of 22.0% (13.9%–
29.7); however, in the previous study, participants' blood glucose
concentration was deliberately kept stable, with a rate of change in
glucose of 0.1 mmol/L/min.18 Furthermore, in the previous study, only
capillary blood glucose concentration was used as a reference and the
performance of the flash GM system was not assessed during meal-
induced and bolus insulin-induced glycaemic challenge. One might
assume that physical exercise per se did not deteriorate the perfor-
mance of the flash GM system, because the rate of change in glucose
appeared to result in inaccuracy. In the present study, the MARD
during exercise was inherently higher than that with other CGM
devices such as Minimed 640G (Medtronic), Dexcom G4 Platinum
(Dexcom) or Paradigm Veo Enlite (Medtronic) (mean absolute relative
difference/MARD, ~18%).6,8,19-21 A systematic overestimation of
2.7 mmol/L might suggest that anticipation of intervention to avoid
exercise-induced hypoglycaemia is required as soon as an interstitial
glucose level of 7.2 mmol/L is reached. This result supports the need
for adjuvant blood glucose measurements during moderate-intensity
exercise, as this inaccuracy leads to wrong clinical decisions that might
entail serious health consequences. Although impairments were found
in sensor performance during exercise, the flash GM system was more
accurate under conditions of lower rates of change in glucose.
When assessing the overall accuracy of the device, based on pre-
specified glycaemic ranges, hypoglycaemia remained the weak spot,
with a MARD of 31.6%. This is contrary to the findings of Aberer
et al., who identified a mean absolute relative difference of 14.6%
with the flash GM system.8 When comparing findings of our study to
those concerning other CGM devices (iPro2, Enlite 2 and Minimed
640G, Medtronic), it appears that hypoglycaemia might be a challenge
to the flash GM system.7 Additionally, during acute exercise accompa-
nied by hypoglycaemia, flash GM data indicated a MARD of 45.1%;
hence, glucose values must be interpreted very cautiously. When eval-
uating performance of the flash GM system according to the guide-
lines for integrated CGM approvals (Class II–510(K), the required
accuracy was achieved only during hyperglycaemia, where 100% of
the interstitial glucose values were within ±40% of the accompanying
venous blood glucose values. Especially during hypoglycaemia, flash
GM interstitial glucose values were far off the expected relative range
(Class II–510(K)). When evaluating the clinical accuracy of the flash
GM system using the Clark error grid, only 56% of values overall and
26% of values during exercise were located in zone A. Additionally,
F IGURE 3 Clinical assessment of the flash GM system and its relationship to reference blood glucose levels using the Clarke error grid. A,
Overall 56% of values were located in zone A, 35% in zone B, 9% in zone D and no values were in zones C and E. B, During exercise, 26% of
values were located in zone A, 52% in zone B, 22% in zone D and no values were in zones C and E
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the fact that 9% of values overall and 22% of values during exercise
were located in zone D clearly indicates that the flash GM system has
major weaknesses, and decisions based on the displayed values are
questionable.
Our study is limited by the rather small number of participants;
however, this limitation was compensated for by four visits in a cross-
over fashion. Additionally, during exercise testing, we analysed the
accuracy of the flash GM system in relation to capillary blood glucose
concentration, which may have resulted in less accurate blood glucose
values.
In conclusion, the flash GM system displayed an impaired perfor-
mance during acute exercise and during periods of hypoglycaemia
where it is inconvenient and difficult to perform capillary blood glu-
cose measurements in individuals with type 1 diabetes. Our results
also demonstrated that the performance of the flash GM system is
linked to the rate of change in blood glucose. Adjuvant blood glucose
measurements are encouraged during physical exercise and/or in the
context of low blood glucose concentrations to avoid episodes of
severe hypoglycaemia as the result of systematic overestimation of
interstitial glucose levels as compared to blood glucose levels.
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